Potential use of histone deacetylase inhibitors in cancer therapy

Area of Science:

• Epigenetics
• Molecular Biology
• Cancer Research

Background:

• Epigenetics involves modifying gene expression without altering DNA sequence, including histone modifications.
• Carcinogenesis is linked to hypoacetylation of genes controlling critical cellular processes like apoptosis, cell cycle, and metastasis.
• Epigenetic therapy is an emerging strategy to counteract cancer-driving epigenetic changes.

Purpose of the Study:

• To review the mechanisms of action for histone deacetylase inhibitors (HDACi).
• To summarize the characteristics of HDACi.
• To present a review of clinical trials involving HDACi and their integration with chemotherapy.

Main Methods:

• Literature review of epigenetic mechanisms in cancer.
• Analysis of histone deacetylase inhibitor characteristics and functions.
• Review of clinical trial data for HDAC inhibitors in cancer treatment.

Main Results:

• Histone deacetylase inhibitors work by reversing gene silencing associated with hypoacetylation.
• HDAC inhibitors have demonstrated potential in modulating cancer-related pathways.
• Clinical trials are evaluating the efficacy and safety of HDAC inhibitors, alone and in combination therapies.

Conclusions:

• Understanding HDAC inhibitor mechanisms is crucial for enhancing their therapeutic efficacy.
• HDAC inhibitors represent a significant area of development in epigenetic cancer therapy.
• Further research and clinical evaluation are needed to optimize the use of HDAC inhibitors in combination with other anticancer agents.